<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761887</url>
  </required_header>
  <id_info>
    <org_study_id>57733</org_study_id>
    <nct_id>NCT04761887</nct_id>
  </id_info>
  <brief_title>Cool Pre-operative TAP Blocks</brief_title>
  <official_title>Pilot Study on the Thermal Effects of Local Anesthetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Wambold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of approximately 20 pre-operative patients scheduled for a transversus&#xD;
      abdominis plane (TAP) block as pain management for a previously scheduled surgery. Subjects&#xD;
      will be randomly assigned to receive either cooled ropivacaine (4째C) during a TAP block or&#xD;
      room temperature (between 20-25째C) ropivacaine during the block. The effects of a TAP block&#xD;
      generally diminish within 24 hours. We believe that cooling ropivacaine before administration&#xD;
      may slightly prolong the analgesic effects of the block and delay time before additional&#xD;
      analgesic is requested, resulting in less opioid use following surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consenting, subjects will be randomized to receive either cooled ropivacaine,&#xD;
      administered at approximately 4째C) or room temperature ropivacaine, administered at&#xD;
      approximately 20-25째C), during an ultrasound-guided TAP block. Time to anesthesia, or loss of&#xD;
      sensation, will be recorded for each subject by a single evaluator, employing the pinch&#xD;
      technique and thermosensory perception, using a glove, filled with a slurry of ice water&#xD;
      placed on both anesthetized and non-anesthetized areas, for approximately 5 seconds. Time to&#xD;
      anesthesia will be recorded when there is a definitive difference on a categorical scale&#xD;
      (painful/not painful or cold/not cold) as measured by the subject, between the anesthetized&#xD;
      and non-anesthetized areas. Safety outcomes and opioid morphine equivalency will be recorded&#xD;
      for all subjects, for approximately 48 hours following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to block of pain and thermosensory perception</measure>
    <time_frame>35 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine equivalency units of adjunct pain medications</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anesthetics, Local</condition>
  <arm_group>
    <arm_group_label>Cool Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine administered at approximately 4C, via a TAP block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Room Temp Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine administered at approximately 20-25C, via a TAP block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cool Ropivacaine Block</intervention_name>
    <description>Ropivacaine is cooled.</description>
    <arm_group_label>Cool Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Room Temp Ropivacaine Block</intervention_name>
    <description>Room Temp Block</description>
    <arm_group_label>Room Temp Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients, aged =18 years of age.&#xD;
&#xD;
          2. Patients, scheduled for surgery, with an order for a TAP block.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of opioid use disorder.&#xD;
&#xD;
          2. Patients, which are scheduled as the first case of the day.&#xD;
&#xD;
          3. Patients with any history of paralysis/palsy.&#xD;
&#xD;
          4. Patients with a history of sensitivity to local anesthetics, including ropivacaine.&#xD;
&#xD;
          5. Patients, whose blocks are scheduled to be administered by a PGY-1 or PGY-2 resident.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Wambold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Wambold, MD</last_name>
    <phone>18593238030</phone>
    <email>daniel.wambold@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Wambold, MD</last_name>
      <phone>859-218-0365</phone>
      <email>daniel.wambold@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Daniel Wambold</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ropivacaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

